Meeting
2018 ASCO Annual Meeting
Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects.
Authors
Sung Yong Oh
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea, Republic of (South)
Sung Yong Oh , Suee Lee , Jung Hun Kang , Seung Tae Kim , Chan Kyu Kim , Joung Soon Jang , In Gyu Hwang , Young Saing Kim , Hee Kyung Ahn , Lee Chun Park , Jun Ho Ji , So Yeon Oh , Seong-Geun Kim , Soonil Lee , Sang-Cheol Lee , Jeeyun Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Late and Long-Term Effects
Clinical Trial Registration Number
NCT02284139
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10054)
DOI
10.1200/JCO.2018.36.15_suppl.10054
Abstract #
10054
Poster Bd #
42
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
First Author: Y. Y. Janjigian
Poster
2023 ASCO Quality Care Symposium
Stomatitis in patients receiving EGFR-targeted therapy for non-small cell lung cancer: A population-based cohort study across the United States.
First Author: Chuan Lu
Poster
2021 ASCO Annual Meeting
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
First Author: Li Zhang
Poster
2018 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Hongyun Zhao